No profile data available.
Senseonics Holdings, Inc. (SENS) is a healthcare company in the chemical laboratory testing equipment industry, based in Germantown, United States, with about 117 full-time employees.
It reported revenue of $35.26 million for fiscal year 2025, up 56.9% from fiscal year 2024, and net income of -$69.11 million. United States was its largest region in fiscal year 2025, with 79% of revenue. Its market capitalization was $274.98 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
Senseonics reported $35.26 million in revenue for fiscal year 2025, up 56.9% from $22.47 million in fiscal year 2024.
United States: 79% of revenue by region in fiscal year 2025, followed by outside of The United States (21%).
$274.98 million as of December 4, 2025.
Listed companies of a similar size in the same industry (chemical laboratory testing equipment) include DexCom, Inc. (DXCM), OraSure Technologies, Inc. (OSUR), Anbio Biotechnology (NNNN), DarioHealth Corp. (DRIO).